Overview Dividends

(GSK) GlaxoSmithKline - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044

Vaccines, Specialty Medicines, Oncology, Respiratory, General Medicines

GSK EPS (Earnings per Share)

EPS Growth (3Y CAGR): -50.52%
EPS Trend (3Y Correlation): -18.3%

GSK Revenue

Revenue Growth (3Y CAGR): 272.10%
Revenue Trend (3Y Correlation): 50.5%

Description: GSK GlaxoSmithKline September 26, 2025

GSK plc (NYSE:GSK) develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the United Kingdom, United States, and global markets, operating through Commercial Operations and Total R&D segments.

Its specialty portfolio targets oncology (e.g., ovarian and endometrial cancers), respiratory-immunology (e.g., eosinophil-driven asthma), inflammation, and HIV-related inhaled therapies, while its vaccine suite spans shingles, RSV, seasonal influenza, HPV, and a broad range of pediatric and adult immunizations.

In 2023, GSK reported revenue of ≈ £34 billion, with a dividend yield of ≈ 5.3% and a free cash flow conversion of ≈ 70%, underscoring its cash-generating capacity despite ongoing pricing pressure in mature markets.

Key sector drivers include an aging global population that expands demand for chronic-disease treatments, heightened public-health focus on vaccine preparedness post-COVID-19, and regulatory trends toward price-cap mechanisms in Europe that compress margins for generic-competitor products.

GSK’s strategic collaboration with CureVac to develop mRNA vaccines for infectious diseases reflects a pivot toward next-generation platform technologies, a move that could diversify its pipeline and mitigate reliance on traditional protein-based vaccines.

For a deeper quantitative assessment of GSK’s valuation metrics, you may find the ValueRay platform useful.

GSK Stock Overview

Market Cap in USD	94,307m
Sub-Industry	Pharmaceuticals
IPO / Inception	1986-07-09

GSK Stock Ratings

Growth Rating	79.7%
Fundamental	74.8%
Dividend Rating	26.3%
Return 12m vs S&P 500	16.7%
Analyst Rating	2.88 of 5

GSK Dividends

Dividend Yield 12m	3.53%
Yield on Cost 5y	5.50%
Annual Growth 5y	-6.74%
Payout Consistency	90.7%
Payout Ratio	55.2%

GSK Growth Ratios

Growth Correlation 3m	92.3%
Growth Correlation 12m	86.2%
Growth Correlation 5y	53.7%
CAGR 5y	18.76%
CAGR/Max DD 3y (Calmar Ratio)	0.66
CAGR/Mean DD 3y (Pain Ratio)	2.11
Sharpe Ratio 12m	1.89
Alpha	23.53
Beta	0.294
Volatility	21.93%
Current Volume	5280.3k
Average Volume 20d	5027.4k
Stop Loss	45.2 (-3.1%)
Signal	0.67

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (15.09b TTM) > 0 and > 6% of Revenue (6% = 17.83b TTM)

FCFTA 0.26 (>2.0%) and ΔFCFTA 18.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.04% (prev -13.29%; Δ 15.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.47 (>3.0%) and CFO 6.09b <= Net Income 15.09b (YES >=105%, WARN >=100%)

Net Debt (-5.57b) to EBITDA (19.19b) ratio: -0.29 <= 3.0 (WARN <= 3.5)

Current Ratio 3.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (NaN) change vs 12m ago NaN% (target <= -2.0% for YES)

Gross Margin 37.69% (prev 72.04%; Δ -34.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 838.2% (prev 53.94%; Δ 784.2pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.89 (EBITDA TTM 19.19b / Interest Expense TTM 640.0m) >= 6 (WARN >= 3)

Altman Z'' 9.22

(A) 0.47 = (Total Current Assets 8.64b - Total Current Liabilities 2.59b) / Total Assets 12.88b

(B) 0.61 = Retained Earnings (Balance) 7.80b / Total Assets 12.88b

(D) 3.05 = Book Value of Equity 9.14b / Total Liabilities 3.00b

Total Rating: 9.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.77

1. Piotroski 4.50pt = -0.50

2. FCF Yield 5.08% = 2.54

3. FCF Margin 1.13% = 0.28

4. Debt/Equity 0.03 = 2.50

5. Debt/Ebitda -0.29 = 2.50

6. ROIC - WACC (= 9.66)% = 12.08

7. RoE 106.6% = 2.50

8. Rev. Trend 50.47% = 3.79

9. EPS Trend -18.33% = -0.92

What is the price of GSK shares?

As of November 08, 2025, the stock is trading at USD 46.63 with a total of 5,280,282 shares traded.
Over the past week, the price has changed by -0.49%, over one month by +7.20%, over three months by +25.45% and over the past year by +33.02%.

Is GlaxoSmithKline a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, GlaxoSmithKline (NYSE:GSK) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 74.77 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GSK is around 49.52 USD . This means that GSK is currently overvalued and has a potential downside of 6.2%.

Is GSK a buy, sell or hold?

GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefor, it is recommend to hold GSK.

Strong Buy: 1
Buy: 0
Hold: 5
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the GSK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	45.9	-1.5%
Analysts Target Price	45.9	-1.5%
ValueRay Target Price	54.6	17%

GSK Fundamental Data Overview November 01, 2025

Market Cap GBP = 71.64b (94.31b USD * 0.7596 USD.GBP)
P/E Trailing = 13.2975
P/E Forward = 8.4388
P/S = 2.9319
P/B = 4.4222
P/EG = 0.3819
Beta = 0.294
Revenue TTM = 297.24b GBP
EBIT TTM = 5.05b GBP
EBITDA TTM = 19.19b GBP
Long Term Debt = 13.70b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 242.0m GBP (from shortTermDebt, last quarter)
Debt = 478.0m GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.57b GBP (from netDebt column, last quarter)
Enterprise Value = 66.07b GBP (71.64b + Debt 478.0m - CCE 6.04b)
Interest Coverage Ratio = 7.89 (Ebit TTM 5.05b / Interest Expense TTM 640.0m)
FCF Yield = 5.08% (FCF TTM 3.35b / Enterprise Value 66.07b)
FCF Margin = 1.13% (FCF TTM 3.35b / Revenue TTM 297.24b)
Net Margin = 5.08% (Net Income TTM 15.09b / Revenue TTM 297.24b)
Gross Margin = 37.69% ((Revenue TTM 297.24b - Cost of Revenue TTM 185.21b) / Revenue TTM)
Gross Margin QoQ = 34.75% (prev 72.89%)
Tobins Q-Ratio = 5.13 (Enterprise Value 66.07b / Total Assets 12.88b)
Interest Expense / Debt = 31.38% (Interest Expense 150.0m / Debt 478.0m)
Taxrate = 34.90% (6.22b / 17.83b)
NOPAT = 3.29b (EBIT 5.05b * (1 - 34.90%))
Current Ratio = 3.34 (Total Current Assets 8.64b / Total Current Liabilities 2.59b)
Debt / Equity = 0.03 (Debt 478.0m / totalStockholderEquity, last fiscal year 13.67b)
Debt / EBITDA = -0.29 (Net Debt -5.57b / EBITDA 19.19b)
Debt / FCF = -1.66 (Net Debt -5.57b / FCF TTM 3.35b)
Total Stockholder Equity = 14.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 117.2% (Net Income 15.09b / Total Assets 12.88b)
RoE = 106.6% (Net Income TTM 15.09b / Total Stockholder Equity 14.16b)
RoCE = 18.12% (EBIT 5.05b / Capital Employed (Equity 14.16b + L.T.Debt 13.70b))
RoIC = 16.85% (NOPAT 3.29b / Invested Capital 19.50b)
WACC = 7.19% (E(71.64b)/V(72.11b) * Re(7.10%) + D(478.0m)/V(72.11b) * Rd(31.38%) * (1-Tc(0.35)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF Debug] Terminal Value 77.05% ; FCFE base≈3.74b ; Y1≈3.45b ; Y5≈3.11b
Fair Price DCF = 27.86 (DCF Value 55.98b / Shares Outstanding 2.01b; 5y FCF grow -9.75% → 3.0% )
EPS Correlation: -18.33 | EPS CAGR: -50.52% | SUE: -4.0 | # QB: 0
Revenue Correlation: 50.47 | Revenue CAGR: 272.1% | SUE: 4.0 | # QB: 1

Additional Sources for GSK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle